Lutetium-177 supply market seen reaching $2.94 billion by 2030

The Business Research Company says the lutetium-177 supply market is moving into a high-growth phase, driven by rising cancer cases, wider use of radiopharmaceutical therapies and expanding isotope production capacity. The market is projected to grow from $1.4 billion in 2025 to $2.94 billion by 2030, with North America leading in 2025 and Asia-Pacific expected to grow fastest.

Why it matters: - Lutetium-177 supply underpins targeted radionuclide therapies used in cancer care, including treatments for neuroendocrine tumors and metastatic prostate cancer. - Rising cancer incidence and broader adoption of precision oncology are pushing demand for the isotope and the manufacturing, logistics and regulatory systems around it. - The projected growth signals more investment in medical isotope production, radiopharmaceutical manufacturing and specialized transport networks.

What happened: - The Business Research Company released its "Lutetium-177 Supply Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report values the market at $1.4 billion in 2025 and projects $1.63 billion in 2026. - The report forecasts the market will reach $2.94 billion by 2030. - The projected CAGR is 15.7% from 2025 to 2026 and 15.9% through 2030. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the report. - View the full report.

The details: - Lutetium-177 supply covers the production, processing and distribution of the radioactive isotope lutetium-177. - The isotope is manufactured using nuclear reactors or cyclotron techniques. - The supply chain requires quality control, specialized packaging, secure transportation and regulatory compliance. - Growth drivers include increasing cancer prevalence, wider clinical acceptance of radiopharmaceutical treatments, expansion in nuclear medicine infrastructure and higher investment in medical isotope production facilities. - The report also cites more regulatory approvals for lutetium-177 therapies as a growth driver. - Looking ahead, demand is expected to be lifted by precision oncology therapies, commercial radiopharmaceutical manufacturing expansion, isotope production technology upgrades, new therapeutic uses and regional isotope supply networks. - Anticipated trends include scaling reactor-based isotope production, strengthening high-purity supply chains, increasing radiopharmaceutical logistics investment, advancing non-carrier-added production methods and improving regulatory-compliant isotope transport. - The World Health Organization projected in February 2024 that new cancer cases could exceed 35 million by 2050, up 77% from about 20 million in 2022.

Between the lines: - The market outlook reflects a broader shift from traditional isotope sourcing toward more resilient and regionally distributed supply chains. - Capacity, logistics and compliance are becoming strategic constraints as radiopharmaceutical therapies move further into mainstream oncology. - The strong regional split suggests mature demand in North America and faster infrastructure buildout in Asia-Pacific. - The report’s added analytics, including TAM analysis, company scoring matrices, forecasting dashboards and market hotspot graphics, signal more competition for investors and suppliers tracking the space.

What's next: - The market is expected to keep expanding as more cancer patients move toward targeted radionuclide therapy. - Suppliers will likely focus on expanding reactor capacity, improving isotope purity and tightening transport systems to meet demand. - Further regulatory approvals and new therapeutic indications could add to market growth through 2030. - The Business Research Company is promoting its 2026 report edition with expanded analytical tools and forecasting resources.

The bottom line: - Lutetium-177 supply is shifting from a niche isotope market into a fast-scaling part of global oncology infrastructure.